林园最新发声：当前A股没有过热 头部公司风险更小 港股已进入牛市

Group 1: Investment Philosophy - The investment philosophy of the company is characterized by a "buy and never sell" approach, which has been maintained over decades in the A-share market [1][7]. - The company emphasizes the importance of forward-looking investment strategies, suggesting that insights should be at least 15 years ahead [5][10]. Group 2: Industry Insights - The company believes that the innovation in traditional Chinese medicine (TCM) does not necessarily require new research but can involve applying ancient formulas to new contexts, especially as the aging population increases [9]. - The company has observed that some TCM companies have maintained a compound annual growth rate of nearly 17% over the past decade, indicating a robust growth potential in the sector [8][9]. - The demand for chronic disease medications is expected to increase significantly, potentially growing tenfold in the next 20 years, particularly among the elderly population [10][11]. Group 3: Market Analysis - The company views the current A-share market as "relatively cold," suggesting that market sentiment often fluctuates due to short-term speculative activities [16][17]. - The company notes that the Hong Kong stock market has entered a bull market, which may influence the A-share market positively [18]. Group 4: Sector Evaluation - The company considers the liquor sector, particularly Chinese liquor, to be undervalued, citing the deep-rooted cultural significance of alcohol consumption in society [14][15]. - Concerns about declining consumption among younger generations are dismissed, as the company believes that alcohol consumption typically increases with age [15].